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Viability and stress protection of chronic lymphoid
leukemia cells involves overactivation of mitochondrial
phosphoSTAT3Ser727
C Capron1,2,3,4,5, K Jondeau2,5,10, L Casetti1,3,4,10, V Jalbert2, C Costa6, E Verhoyen6,7, JM Massé1,3,4, P Coppo8, MC Béné9,
P Bourdoncle1,3,4, E Cramer-Bordé1,2,3,4,5 and I Dusanter-Fourt*,1,3,4
Chronic lymphoid leukemia (CLL) is characterized by the accumulation of functionally defective CD5-positive B lymphocytes. The
clinical course of CLL is highly variable, ranging from a long-lasting indolent disease to an unpredictable and rapidly progressing
leukemia requiring treatment. It is thus important to identify novel factors that reflect disease progression or contribute to its
assessment. Here, we report on a novel STAT3-mediated pathway that characterizes CLL B cells-extended viability and oxidative
stress control. We observed that leukemic but not normal B cells from CLL patients exhibit constitutive activation of an atypical
form of the STAT3 signaling factor, phosphorylated on serine 727 (Ser727) in the absence of detectable canonical tyrosine 705
(Tyr705)-dependent activation in vivo. The Ser727-phosphorylated STAT3 molecule (pSTAT3Ser727) is localized to the mitochondria
and associates with complex I of the respiratory chain. This pSer727 modification is further controlled by glutathione-dependent
antioxidant pathway(s) that mediate stromal protection of the leukemic B cells and regulate their viability. Importantly,
pSTAT3Ser727, but neither Tyr705-phosphorylated STAT3 nor total STAT3, levels correlate with prolonged in vivo CLL B cells
survival. Furthermore, STAT3 activity contributes to the resistance to apoptosis of CLL, but not normal B cells, in vitro. These data
reveal that mitochondrial (Mt) pSTAT3Ser727 overactivity is part of the antioxidant defense pathway of CLL B cells that regulates
their viability. Mt pSTAT3Ser727 appears to be a newly identified cell-protective signal involved in CLL cells survival. Targeting
pSTAT3Ser727 could be a promising new therapeutic approach.
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Chronic lymphoid leukemia (CLL) is characterized by the
accumulation of proliferating CD5+ B lymphocytes.1 The
clinical course of CLL is highly variable, ranging from a long-
lasting to a rapidly progressing leukemia requiring treatment.
Although the understanding of CLL pathophysiology has
improved markedly in the past few years, therapeutic
approaches are still not curative. It is thus important to further
identify the factors that selectively sustain CLL cells survival.
CLL B lymphoid cells (CLL-BCs) have a prolonged survival
time in vivo but exhibit a high level of spontaneous apoptosis
in vitro, highlighting the critical role of CLL-BC microenviron-
ment in this pathology.1–3 Several stromal factors have been
shown to be implicated in promoting CLL-BC viability in vitro,4–6
yet the exact mechanisms by which the microenvironment
protects CLL cells from apoptosis in vivo remain unclear.
The STAT3 signaling factor mediates numerous extra-
cellular survival/growth messages. It is activated by phosphor-
ylation of tyrosine 705 (Tyr705), allowing STAT3 to bind to DNA
and activate the transcription of target genes.7 Abnormal
constitutive activation of Tyr705-phosphorylated STAT3
(pSTAT3Tyr705) is observed in multiple tumor cells and
contributes to oncogenic processes.8,9 In addition, STAT3
can be phosphorylated at serine 727 (Ser727) by growth factor-
activated serine kinases, thereby modulating STAT3 transcrip-
tional activity and regulating the activity of associated
transcriptional factors such as NFκB.10 Remarkably, STAT3
was recently reported to exhibit extranuclear pro-oncogenic
activities in murine cells, linked to its mono-phosphorylation on
Ser727 but not Tyr705, subsequent association with mitochon-
drial (Mt) components and regulation of the respiratory
chain.11,12 In 1997, Frank and Mahajan13 showed by western
blotting a remarkable constitutive phosphorylation of STAT3-
Ser727 in the absence of canonical pSTAT3Tyr705 in 100% of
32 primary CLL-BC samples. Hazan-Halevy et al.14 later
showed that STAT3 limited the spontaneous apoptosis of
CLL-BC in vitro.
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In the present study, we addressed the role of
Ser727-phosphorylated STAT3 (pSTAT3Ser727) in CLL
pathophysiology. We demonstrate that circulating CLL-BCs
but not normal B lymphoid cells (N-BCs) overexpress
an atypical mitochondria-associated pSTAT3Ser727 moiety,
the level of which correlates with prolonged CLL-BC survival
in vivo. We further identified glutathione (GSH), an antioxidant
mediating stromal protection of the leukemic cells, to be a
critical regulator of Ser727 phosphorylation, and provide
evidence that STAT3 is responsible for the extended survival
of CLL-BC as compared with N-BC. Overall, our data suggest
that Mt pSTAT3Ser727 contributes to the protection of CLL-BC.
As such, it may represent a new biochemical pathway for
effectively targeting leukemia cells, especially those that
exhibit drug resistance.
Results
Overactivation of pSTAT3Ser727 correlates with CLL-BC
resistance to apoptosis. Circulating B cells were purified
from healthy donors (n=8) and CLL patients (Supplementary
Table 1). Samples were studied immediately upon collection
to avoid any culture artifacts owing to the spontaneous
apoptosis of these cells in vitro. Apoptosis was measured by
combining Annexin V/7-AAD (7-aminoactinomycin D) stain-
ing of phosphatidyl serine externalization and dead cell DNA
labeling. Apoptosis was also assessed by monitoring the Mt
transmembrane potential (MTP) that characterizes mitochon-
dria in viable cells. CLL-BC showed significantly lower
apoptosis than N-BC using both assays, consistent with the
extended survival of CLL-BC in vivo (Figure 1a and data not
shown). The intensity of this labeling was variable from
patient to patient, which is in agreement with the hetero-
geneity of CLL disease. STAT3 phosphorylation was inves-
tigated by flow cytometry measurements (FCMs). As shown
in Figure 1b, CLL-BC showed strong immunolabeling using
an anti-pSTAT3Ser727 antibody. This labeling was abolished
by the pSTAT3Ser727 immunogen peptide (ipep) as well as by
an 11 amino-acid-long STAT3Ser727 phosphopeptide but not
by the unphosphorylated peptide, thus confirming labeling
specificity. Conversely, quite low pSTAT3Ser727 immunolabel-
ing was detected in N-BC under similar conditions, although
pSTAT3 Ser727 was normally induced by phorbol esters in
these cells (Figure 1b, left panel). Statistical analyses
confirmed that circulating CLL-BC expressed higher levels
of pSTAT3Ser727 as compared with N-BC (Figure 1c).
Regarding pSTAT3Tyr705, CLL-BC and N-BC showed a
similar weak-to-undetectable immunolabeling (Figure 1d). In
addition, CLL-BC and N-BC expressed the same total STAT3
levels (Figure 1e). Western blot analysis of the same cells
confirmed that CLL-BC overexpressed pSTAT3Ser727 as
compared with N-BC in the absence of detectable pSTAT3-
Tyr705. Also, no activation of the related STAT5 factor was
observed (Supplementary Figure 1).
The highly variable course of CLL led us to compare
pSTAT3Ser727 levels with the apoptosis indexes of CLL-BC.
A significant negative correlation was observed between
pSTAT3Ser727 level and the percentage of apoptotic Annexin
V-positive CLL-BC (Figure 1f, right, n=29). Conversely,
pSTAT3Ser727 levels showed a positive correlation with the
mitochondria transmembrane potential (MTP) that labeled
viable cells (Figure 1g, right, n= 29). Notably, no correlation
was observed between total STAT3 levels and CLL-BC basal
apoptosis using both criteria. These data indicate that CLL-
BC-extended survival correlates with pSTAT3Ser727 activation
in the absence of pSTAT3Tyr705 activation and total STAT3
amplification. This suggests that pSTAT3Ser727 contributes to
CLL-BC leukemic properties in vivo.
pSTAT3Ser727 localizes to CLL-BC mitochondria. A single
serine phosphorylation was shown to mediate STAT tran-
scription activation.15 We determined whether CLL-BC
pSTAT3Ser727 binds DNA. CLL-BC nuclear extracts were
prepared and pull-down experiments using biotin-labeled
STAT3-DNA probes were performed. pSTAT3Ser727 was
mostly undetectable in the nuclear fraction. Neither STAT3
nor pSTATSer7227 did bind STAT3-DNA elements (Figure 2a
and data not shown). pSTAT3Ser727 localization was next
examined using immunolabeling coupled to confocal micro-
scopy. In CLL-BC, pSTAT3Ser727 distributed to the cytoplasm
with a clear granular pattern but no significant nuclear
labeling (Figure 2b, top). All fluorescence was suppressed
when the rabbit anti-pSTAT3Ser727 antibody was pre-mixed
with an excess amount of ipep (Figure 2b) or with pS3-11pep
but not with the unphosphorylated STAT3 (S3)-11pep
(Supplementary Figure 2). Compared with CLL-BC, N-BC
showed weak-to-undetectable pSTAT3Ser727 labeling
(Figure 2b). Immunolabeling of total STAT3 showed a rather
uniform cellular distribution in CLL-BC and N-BC (Figure 2b).
The peculiar intracellular distribution of pSTAT3-Ser727
suggests an association with cytoplasmic organelles.
Because of the reported Mt activities of STAT3,12 the
important involvement of mitochondria in cell survival and
the increased MTP of CLL-BC (Figure 1), we focused on
these organelles. Mitotracker, a selective dye that concen-
trates into mitochondria along MTP, was first used to visualize
these organelles. pSTAT3-Ser727 was observed within
Mitotracker-positive subcellular areas in co-labeling assays
(Figure 2b). An additional experiment was performed using a
murine monoclonal anti-pSTAT3Ser727 antibody that con-
firmed the predominant granular cytoplasmic localization of
pSTAT3Ser727 in CLL-BC (Figure 2c). Mitochondria were co-
labeled by antibodies directed to the Mt electron transfer
chain (ETC) complex I NADH-ubiquinone reductase subunit
(mtND1).16 pSTAT3-Ser727 immunolabeling again co-
localized with this second Mt marker, as assessed by
line-scan fluorescence quantification (Figure 2c).
Co-labeling was further ascertained at the pixel level using
Pearson’s correlation coefficient measurement that validated
pSTAT3Ser727/mitochondria co-localization statistically in
patient samples (Figure 2d).
B lymphocytes are small cells with a very limited cytoplas-
mic area. pSTAT3Ser727 intracellular distribution was further
analyzed using transmission electronmicroscopy. As shown in
Figure 3a, CLL-BC contained significantly more mitochondria
as compared with N-BC (10.6± 0.45 versus 7.5±0.17,
Po0.01), which filled most of the cytoplasmic area. Immuno-
gold labeling, performed on ultrathin sections, revealed the
presence of immunoreactive pSTAT3Ser727, predominantly
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localized in CLL-BC mitochondria (Figure 3b). No signal was
detected in N-BC nor in CLL-BC stained in the presence of the
ipep (data not shown). By contrast, immunolabeling of total
STAT3 revealed the presence of STAT3 moieties in all cell
compartments, including mitochondria, in both CLL-BC and
N-BC (Figure 3c).
pSTAT3Ser727 intracellular localization was also assessed
by subcellular fractionation. Mitochondria were isolated from
cell lysates by magnetic labeling with antibodies directed
to the translocase of the outer Mt membrane 22 (TOM22).
Mitochondria enrichment was evaluated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) coupled to
immunoblotting using the Mt heat-shock protein 60 (hsp60)
and NADH dehydrogenase 1 alpha subunit 9 (NDUFA9), a
component of complex I of the ETC, cytoplasmic β-actin
and nuclear lysine demethylase 1a (KDM1a; Figure 4a).
STAT3 and pSTAT3Ser727 associate with β-actin- and
KDM1a-negative mitochondria-enriched fraction. Comparison
of the amounts of STAT3 and hsp60 in TOM22-positive and
-negative fractions indicated that levels of Mt STAT3 were
~ 1–5% that of total STAT3. First, evidence for the Mt
localization of STAT3 has come from observations that
GRIM-19, a component of the ETC complex I, directly binds to
STAT3.12 Using an antibody that captures all components of
complex I and immunoprecipation assays, we co-precipitated
serine phosphorylated STAT3 in CLL-BC, but not in N-BC
extracts (Figure 4b).
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Figure 1 Activation of pSTAT3Ser727 correlates with CLL-BC resistance to apoptosis. (a) Flow cytometry measurement (FCM) of B-cell apoptosis by Annexin V staining of
CD45+CD19+ normal (N-BC) and CLL (CLL-BC) B cells. (b–e) FCM of pSTAT3Ser727 (b and c), STAT3Tyr705 (d) and total STAT3 (e) of N-BC and CLL-BC. (b) One representative
experiment is shown. B cells were labeled with rabbit control (dashed black line), total STAT3 or pSTAT3Ser727 antibodies, as indicated, in the absence (blue line) or presence of
pSTAT3Ser72 immunogen peptide (ipep; green line), phosphorylated S3Ser727 11-peptide (red line) or unphosphorylated S3Ser727 11-peptide (purple line). The black line
indicates pSTAT3Ser727 labeling following a 15-min treatment of N-BC with phorbol myristyl acetate. Results are expressed as mean fluorescence intensity (arbitrary unit, a.u.).
(c–e). Statistical analyses of the indicated immunolabeling mean fluorescence intensities are shown (N-BC, n= 8; CLL-BC, n= 29; **Po0.01). (f and g) Correlation between
pSTAT3Ser727 or total STAT3 levels (mean fluorescence intensity) and the percentage of apoptotic Annexin V-positive cells (f) or DiOC6-probed mitochondrial transmembrane
potential (G), evaluated in CLL-BC samples (r, Pearson’s coefficient; n= 29)
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Collectively, these data concur in indicating that CLL-BC
display overactivation of an atypical Mt pSTAT3Ser727 moiety.
CLL-BC oxidative stress regulates Mt pSTAT3Ser727
activation. In vivo, their microenvironment has a profound
effect on CLL-BC survival. Stromal support of CLL-BC can be
reproduced when they are co-cultured with bone marrow
stromal cell lines.6,17 Indeed, murine MS5 and human HS5
cells significantly reduce the level of CLL-BC spontaneous
apoptosis, as assessed by Annexin V labeling and MTP
probing (Figures 5a and b and Supplementary Figure 3). It
similarly maintains a strong level of pSTAT3Ser727 immuno-
labeling in absence of any immunoreactive pSTAT3Tyr705 in
CLL-BC even after prolonged periods (Figures 5c and d, right
panels, and Supplementary Figure 3), while the expression
of total STAT3 remains unchanged (data not shown).
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Figure 2 pSTAT3Ser727 subcellular localization characterizes human primary CLL B cells. (a) Nuclear extracts from CLL-BC (#n upper panel, lower panel) or UT7
hematopoietic cell line were prepared and incubated with biotin-labeled STAT3-binding site DNA probes and streptavidin magnetic beads for pull-down assays. Attached proteins
were separated by SDS-PAGE and STAT3 was detected by immunoblotting. NE and OP indicate nuclear extracts and oligo-pull-down extracts, respectively; 1:100 of total NE were
loaded on each gel. NE were incubated with biotin-labeled SIEm67- (upper panel) or with SIEm67 (S), IRF (I)- or Oct (O)-DNA (lower panel) probes; lo and hi indicate low and high
exposure of the immunoblot. UT7 hematopoietic cells were pre-incubated for 15 min in the absence or presence of phorbol myristyl acetate (P) as positive controls. α and β
indicate STAT3α and STAT3β isoforms. (b–d) CLL-BC and N-BC were isolated, fixed, permeabilized and processed for fluorescence confocal microscopy as indicated.
(b) Rabbit (rb) anti-pSTAT3Ser727 (pS3Ser727) antibody in the absence or presence of immunogen peptide (ipep), rabbit anti-total STAT3 (total S3) and isotype control
rabbit immunoglobulins (rb Ig) were used in co-labelings with mitotracker, as indicated. DIC indicates differential interference contrast. (c) Mouse anti-pSTAT3Ser727
(pS3Ser727 mAb) and rabbit anti-mtND1 antibodies were used in co-labeling assays. Fluorescent probes were FITC-coupled anti-rabbit Ig (rb Ig-FITC, green), red-mitotracker or
PE-coupled anti-mouse Ig (red), DAPI (blue). Line scan intensity profiles (bottom) of pS3Ser (red), mtND1 (green) and DAPI (blue) labeling along indicated axes (x1–y1; x2–y2)
from gated areas. DAPI-positive nuclear (N) and DAPI-negative cytoplasmic (C) areas are schematized. Representative images from five patients (#n relates to Table I patient’s
number) and five healthy donor samples are shown. Magnification, × 100. (d) Pearson’correlation coefficients were measured for the indicated fluorescent signals (rabbit anti-
pSTAT3Ser727 versus mitotracker; mouse anti-pSTAT3Ser727 versus rabbit anti-mtND1; mouse anti-pSTAT3Ser727 versus DAPI). Twenty-five cells were randomly examined in
confocal microscopy for each patient, and data from five and three patients were pooled, which corresponds to over 100 cells observed; **Po0.01)
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Under similar conditions, stromal cells enhance not only
pSTAT3Ser727 but also pSTAT3Tyr705 activation of N-BC in a
time-dependent manner.
pSTAT3Ser727 localization was assessed in this model.
Using again two different pSTAT3Ser727 antibodies and
mitochondria markers, CLL-BC were shown to display the
same predominant Mt localization of pSTAT3Ser727 upon MS5
co-culture, as compared with freshly isolated CLL-BC
(Figure 5e and data not shown). Conversely, a pronounced
difference was observed in stroma co-cultured N-BC in which
pSTAT3Ser727 was distributed to the cytoplasmic and nuclear
compartments, and thus not predominantly associated to
mitochondria.
Collectively, these observations indicate that stromal cells
mimic in vitro the interactions between CLL-BC and their
microenvironment that occur in vivo, in terms of CLL-BC
protection from apoptosis, STAT3 phosphorylation status and
intracellular localization. They further reveal that the same
stromal messages are differentially received and translated by
N-BC and CLL-BC, thereby leading to mitochondria-restricted
pSTAT3Ser727 overexpression in leukemic cells only.
The accumulation of Mt pSTAT3Ser727 in stroma-supported
CLL-BC led us to search for stromal signals that would
regulate pSTAT3Ser727 activation in these cells. CLL-BC
intrinsically have high levels of reactive oxygen species
(ROS) when compared with normal lymphocytes.1,18 This
makes CLL-BC more dependent on such cellular antioxidants
as GSH. A critical metabolic interaction between CLL-BC and
bone marrow stromal cells was recently reported to enhance
GSH synthesis, and thus increase the ability of CLL-BC to
maintain the redox balance and promote cell survival.6 We
tested the relationship between GSH, oxidative stress and
pSTAT3Ser727 expression of CLL-BC. Dihydroethidium (DHE)
provides a clear indication of primary ROS levels19 by binding
to superoxide anions that are produced predominantly by the
respiratory chain of mitochondria in most cells except
phagocytes. As shown in Figure 6a, the addition of GSH to
CLL-BC culture medium, in absence of stromal cells, indeed
enhanced ROS detoxification, thereby lowering superoxide
anions levels and promoting cell survival. It further enhanced
pSTAT3Ser727 expression of CLL-BC without changing
pSTAT3Tyr705 activation (data not shown) and total STAT3
levels. Similar data were obtained upon addition of N-acet-
ylcysteine (NAC), another antioxidant. This increased activa-
tion of pSTAT3Ser727 by antioxidants targeted Mt STAT3, as
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assessed by immunolabeling coupled to confocal microscopy
(data not shown).
Conversely, the viability of CLL cells can be decreased by
depletion of GSH using β-phenylethyl isothiocyanate (PEITC),
a natural compound capable of inactivating cellular GSH and
modulating ETC activity. PEITC indeed significantly enhanced
intracellular ROS levels of CLL-BC (Figure 6b). It also
decreased CLL-BC levels of pSTAT3Ser727 in a
concentration-dependent manner while it had no impact on
total STAT3 expression. It further suppressed GSH- and NAC-
dependent regulation of ROS and pSTAT3Ser—but again not
total STAT3–expression. Notably, the inhibitory activity of
PEITC was time dependent, with a significant pSTAT3Ser727
loss being detectable at 1 h of treatment. This effect was
observed when CLL-BCs were cultured alone (Figure 6c) or
with stromal cells (data not shown), and were detectable
before substantial ROS increase. These data suggest that the
oxidative stress status of CLL-BC regulates pSTAT3Ser727.
ROS directly affects the activity of a large number of cellular
proteins. It also regulates the amounts of reduced GSH, which
in turn positively or negatively modulate protein activity
through direct conjugation, that is, glutathionylation, as
observed for such Ser/Thr kinases as MEK and JNK,
which may mediate GSH-dependent Mt STAT3Ser727
phosphorylation.20 The MEK–ERK pathway is required for
Ras-induced phosphorylation of Mt STAT3 on Ser727, which is
one of the critical steps of the Ras-MEK–ERK axis during
transformation.21 Pharmacological inhibition of MEK, how-
ever, did not affect serine phosphorylation of STAT3 in CLL-BC
(Figure 6d).
Altogether, these data suggest that the oxidative stress
status of CLL-BC regulates pSTAT3Ser727 activation through a
MEK–ERK independent pathway.
STAT3 sustains CLL-BC survival. The role of STAT3 in
mediating the protection of CLL-BC was next investigated by
an RNA interference-based strategy. Small hairpin RNA
(shRNA) that knocks down human STAT3 (shS3) was stably
Figure 5 Stromal protection of CLL-BC sustains Mt pSTAT3Ser727 overactivation. (a and b) FCM of apoptosis (a) and mitochondrial transmembrane potential (MTP; b) of
N-BC and CLL-BC at day 8 of MS5 co-culture. Results are expressed as percentage of AnnexinV-positive (a) and TMRM-positive (MTP+; b) cells. The mean +/ S.E.M. of
3 independent experiments is shown, *Po0.05; **Po0.01. (c and d) FCM analysis of pSTAT3Ser727 (c) or pSTAT3Tyr705 (d) expression in N-BC and CLL-BC upon MS5 co-
culture. CD45+CD19+ CD5+ B cells were analyzed at day 0 (blue), day 3 (purple) or day 8 (red) of MS5 co-culture. Standard rabbit immunoglobulins were used as control at day 8
(dashed black line). One representative experiment is shown (samples from three healthy donors and three individual patients were analyzed). Results are expressed as mean
fluorescence intensity (arbitrary unit, a.u.). (e) N-BC and CLL-BC were collected at day 8 of MS5 co-culture. Immunofluorescence analyses were performed with the indicated
primary antibodies using fluorescence microscopy (magnification × 100). Fluorescent probes were FITC-coupled anti-rabbit Ig (green), PE-coupled anti-mouse Ig (red) and DAPI
(blue). DIC indicates differential interference contrast. Representative images from three CLL patients and five healthy donors are shown
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introduced in N-BC and CLL-BC, using a lentiviral vector that
co-encodes the green fluorescent protein (GFP) dye.
Lentiviral particles that expressed measles virus glycoprotein
envelope instead of canonical vesicular stomatitis virus
glycoprotein were used to allow efficient transduction of
human B cells, as we reported previously.22 shRNA targeting
luciferase (shL) or STAT5 (shS5) were used as controls. As
shown in Figures 7a and b, shS3 decreased STAT3 gene
expression, with no impact on STAT5 levels as compared with
control shRNA (shL)-expressing human RAJI B cells, which
validated the shS3 specificity. This was confirmed on CLL-BC
by FCM. Transduced CLL-BC were maintained on MS5
stromal cells and the level of apoptosis of GFP+ and GFP−
subsets were analyzed along the period of culture, using
AnnexinV labeling and tetramethylrhodamine-methyl-ester
(TMRM) MTP probing, together with dead cell DNA staining
by 7AAD or TOPRO-3 dyes. By all criteria, shS3+/GFP+ CLL-
BC exhibited enhanced apoptosis as compared with shS3-/
GFP- and shL+/GFP+ control cells, whereas the viability of
shS5+/GFP+ CLL-BC was unchanged (Figures 7c–e). Nota-
bly, shS3 suppressed the enhanced viability of CLL-BC,
whereas it had no consequences on N-BC under similar
conditions (Figures 7d and e). These data indicate that
STAT3, but not STAT5, selectively supports CLL-BC survival
in the absence of canonical pSTAT3Tyr705 activation.
Discussion
In the present study, we investigated the physiopathological
role of STAT3 phosphorylation in the natural history of CLL
disease. Using human primary B cells from healthy donors
and CLL-BCs from patients, this study shows that CLL-BC but
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not N-BC exhibit an over-activation of an atypical
mitochondria-associated pSTAT3Ser727 moiety that charac-
terizes leukemic cells survival and oxidative stress control.
Four key results support these conclusions. First, circulating
CLL-BC spontaneously express an abnormally high level of
the mitochondria-restricted pSTAT3Ser727 moiety in the
absence of canonical pSTAT3Tyr705 activation, at variance
with what is observed in N-BC in vivo. Second, stroma-
supported CLL-BCs, but not N-BCs, exhibit overactivation of
the Mt pSTAT3Ser727 moiety in vitro. Third, both inhibitors and
activators of the antioxidant GSH pathway, which regulates the
redox balance and survival of CLL-BC, similarly regulate CLL-
BC Mt pSTAT3Ser727. Fourth, the extended survival of CLL-
BC correlates with their pSTAT3Ser727 status but not overall
STAT3 expression level in vivo and rely on STAT3 activity, as
opposed to what was observed in N-BC.
Several reports have shown that pSTAT3Ser727 activation
in the absence of canonical pSTAT3Tyr705 mediates cell
survival messages, as illustrated by the action of neutrotro-
phins on both neuronal stem/progenitor and mature cells, or
VEGF activity on CLL-BC cultured alone.23–26 DNA damage
inducers similarly activate pSTAT3Ser727 but not pSTAT3-
Tyr705 expression in cancer cell models, thereby enhancing
DNA repair.27 In these analyses, pSTAT3Ser727 activity
involved nuclear transcriptional regulation of cell survival/
DNA repair genes. Our study reveals that CLL-BC exhibit a
uniqueMt pSTAT3Ser727 overactivation not observed in N-BC.
Wegrzyn et al.12 have indicated that Mt pSTAT3Ser727
enhanced mitochondria respiration of murine normal primary
B cells, yet without impacting their survival. It however
protected murine cardiomyocytes from ischemia and
decreased the production of ROS and cytochrome-c
release.28 Also, Mt pSTAT3Ser727 is involved in nerve growth
factor-induced neurite outgrowth and the production of ROS.29
Remarkably, Mt pSTAT3Ser727 is overexpressed by Ras-
transformed mouse embryo fibroblasts and supports Ras-
dependent malignant transformation.11 It further influences
the tumorigenic potential of murine 4T1 breast cancer cells
that correlates with the regulation of ROS concentrations.30
Here our observations consistently disclosed that human
primary CLL-BC spontaneously exhibit overactivation of Mt
pSTAT3Ser727 as compared with their normal counterparts, a
feature that is linked to their extended survival and oxidative
stress control. To our knowledge CLL is the first human
malignancy linked to a non-canonical mitochondria-restricted
pSTAT3Ser727 overactivity in vivo.One prominent biochemical
feature of CLL-BC is their high level of ROS and oxidative
stress, when compared with normal lymphocytes. This ROS
stress renders them dependent on proper redox balance and
makes them oversensitive to agents that induce further ROS
stress.31,32 Interestingly, we observed that CLL-BC exhibit an
abnormal accumulation of Mt mass, which is in agreement
with the data reported by Carew et al.18 The deregulated
mitochondria biogenesis in CLL-BC is significantly related to
endogenous ROS levels and further correlates with enhanced
drug resistance.18 GSH is the most abundant antioxidant in
cells and significantly affect cell survival.33 Indeed, CLL-BC
from patients exhibit deficient GSH synthesis and rely on
stromal cells to provide cysteine for GSH production.6 Our
study reveals that the oxidative stress status of CLL-BC, which
is controlled by cell microenvironment and dictates leukemic
cell apoptosis resistance, also regulates the activation of Mt
pSTAT3Ser727 in CLL-BC in a dose-dependent and rapid
manner (o1 h), and also in absence of the active MEK–ERK
pathway. It indicates that various signaling pathways can
modulate serine phosphorylation of Mt STAT3 in tumor cells.
We have tested a number of inhibitory agents to decipher
which kinase(s) might phosphorylate STAT3Ser727 of CLL-BC.
They included PI3k inhibitors (Ly294002, Wortmanin), mTOR
inhibitors (rapamycin and AZD8055) and many others (data
not shown). GSH activators and inhibitors were the very first
ones to affect pSTAT3Ser727 of CLL-BC. Clearly, more work
needs to be done for pSTAT3Ser727 mode of activation in CLL-
BC. Our observation that the GSH antioxidant pathway
regulates pSTAT3Ser727 expression questions whether
pSTAT3Ser727 effectors may influence ROS production.
pSTAT3Ser727 associates with complex I of CLL cells. In the
presence of increased ROS, STAT3 can be oxidized to form
multimers.34 An alternative oxidative modification of STAT3 by
S-glutathionylation has also been observed.35 Complex
I-associated STAT3 of CLL-BC may thus limit ROS production
by decreasing electron leak of complex I and/or by serving as a
critical electron scavenger, as previously suggested.28–30
In vivo, the microenvironment has a profound effect on CLL-
BC survival. Besides BCR signaling, several stromal factors
have been implicated in sustaining CLL-BC survival. A number
of these factors activate not only pSTAT3Tyr705 but also
pSTAT3Ser727 in N-BC and CLL-BC when added to culture
medium separately in the absence of stromal cells.4,5,23 Our
study now reveals that the mixed protective signals provided
by stromal microenvironments in vivo and ex vivo (i.e., MS5/
HS5) are all combined to a unique mitochondria-associated
overactivation of pSTAT3Ser727 in the absence of canonical
activation of pSTAT3Tyr705 in CLL-BC but not N-BC. It provides
substantial evidence that the same stromal signals are
differentially translated by CLL-BC and N-BC. Thus, stromal
support of leukemia cells correlates with major intrinsic
qualitative changes in CLL-BC signaling pathways leading to
pSTAT3Ser727 overactivation, as compared with N-BC. Our
data show that this pSTAT3Ser727 overactivation is not
associated with massive STAT3 delocalization. Indeed,
immunolabelings of human normal and leukemic B cells
detected the presence of reasonable levels of Mt STAT3,
which is confirmed by subcellular fractionation. This suggests
that constitutive phosphorylation of STAT3Ser727 occurswithin
the mitochondria of CLL-BC. As opposed to our data, previous
reports showed that aminor proportion of total STAT3 localizes
to mitochondria upon fractionation of normal cells.11,12,36 One
interpretation of this discrepancy is that part of Mt STAT3 is lost
upon mitochondria isolation based on different subcellular
fractionation protocols. Also, CLL-BC contain significantly
more mitochondria as compared with N-BC. Mt STAT3 of CLL-
BC might therefore be more abundant and/or less labile as
compared with other cells. Also, our data indicate that nuclear
pSTAT3Ser is undetectable and unable to bind STAT3-DNA-
specific probes in CLL-BC. This is in contradiction with the
previously reported nucleocytoplasmic trafficking of pSTAT3-
Ser727 in CLL-BC, despite the use of an identical STAT3-DNA
probe.14 Again, different subcellular fractionation and/or pull-
down protocols may explain such a discrepancy.
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Overall, our findings indicate that Mt pSTAT3Ser727 over-
activation is linked to leukemic B cell-extended survival and
antioxidant defense. It suggests that pSTAT3Ser727 contributes
to the antioxidant defense and protection of the leukemic cells.
This activity may similarly reduce that of ROS-generating
anticancer agents and favor drug resistance. These results
suggest that pSTAT3Ser727 detection could be used as a new
tool to characterize patients’ leukemic cells from blood samples,
which, together with current disease criteria, could help define
newpatient subgroups and help predict disease outcome and/or
drug resistance. It further supports the idea of therapeutically
targeting pSTAT3Ser727 activity to deregulate leukemic cell
antioxidant defense and eliminate theCLL-BC protected by their
microenvironment, which could be resistant to immune chemo-
therapy. To our knowledge, CLL is the first human malignancy
linked to a non-canonical mitochondria-restricted pSTAT3Ser727
overactivity in vivo, thereby offering a new potential therapeutic
target that spares healthy B cells.
Materials and Methods
Primary cells and cell lines. After obtaining the approved informed consent
of Institutional Review Board, peripheral blood mononuclear cells were collected
from healthy donors and CLL patients, and were isolated by density-gradient
centrifugation on Ficoll Hypaque. B cells were further purified using CD3/CD14
immunomagnetic-bead-negative selection (Miltenyi Biotec, Cologne, Germany) to
avoid B-cell activation. CD5/CD19 double-positive cells were selected by FACS. All
patients had immunophenotypically defined CLL as outlined by the modified 1996
National Cancer Institute Criteria (Supplementary Table 1). The RAJI human B-cell
line, the MS5 murine and HS5 human bone marrow stromal cell lines were
purchased from DSMZ cell depository bank. They were cultured in RPMI (RAJI) and
MEM alpha (MS5, HS5) medium supplemented with 10% fetal calf serum (FCS). B
cells were cultured in vitro alone or with a layer of HS5 or MS5 cells under normoxia
in RPMI medium supplemented with 5–10% FCS. The cells were incubated with
GSH (2 mM) or NAC (1 mM) for 4 days and exposed to PEITC (0–5 μM) during the
last 5 h of incubation. Alternatively, B cells were exposed to PEITC (0–5 μM) alone
for 0–5 h. Where indicated, CLL-BC were cultured alone for 2 days in the absence
or presence of the MEK inhibitor PD0325901 (0–100 nM).
Lentiviral constructs and transduction. Oligonucleotides targeting
firefly luciferase (shL, 5′-CGTACGCGGAATACTTCGA-3′), STAT3 (shS3,
5′-AAGAAACTGGAGGAGTTGCAG-3′) and STAT5A/B (shS5, 5′-GGAGA
ACCTCGTGTTCCTG-3′) were inserted downstream of the H1 promoter into an
HIV-SIN-SFFVGFP vector that encodes GFP as reporter. Lentiviral particles
displaying measles virus glycoproteins were produced and titrated on 293T cells
using GFP FCM as described. B cells were incubated with lentiviral particles at a
multiplicity of infection of 3 in RPMI1640 supplemented with 10% FCS for 18–24 h
and then transferred on MS5 stromal cells for at least 8 days. Transduction
efficiencies ranged between 10 and 30%.
Flow cytometry measurements. CLL-BC were identified by anti-CD5-APC-
Cy7 and anti-CD19-PC7 antibodies. Apoptosis was assessed by Annexin V labeling.
MTP measurements were achieved using 3.3′dihexyloxacarbocyanine iodide (Di0C6(3))
or TMRM fluorescent probes, sequestered by active mitochondria.37 Dead cells were
stained by 7-AAD or TO-PRO-3 iodide (Life Technologies, Carlsbad, CA, USA). ROS
were evaluated using the DHE fluorescent probe that binds to superoxide anions. For
STAT3 and pMEK labeling, CD5+CD19+ pre-labeled B cells were fixed, permeabilized
and incubated with relevant antibodies, according to Irish et al.38 The antibodies were
total STAT3, pSTAT3Tyr705, pSTAT3Ser727 and pMEK (BD Biosciences, San Jose, CA,
USA). pSTAT3-Ser727 antibodies were pre-mixed or not with pSTAT3-Ser727 ipep (Santa
Cruz, Dallas, TX, USA) or a chemically synthesized STAT3 peptide (IDLPMS727PRTLD)
that was phosphorylated (pS3-11pep) or not (S3-11pep) on Ser727 (Thermo Fisher
Scientific, Waltham, MA, USA) at a 1 : 100 molar ratio. FCM analyses were performed
using Diva and Cellquest on a FACS-Canto II (BD Biosciences). Data are expressed as
the percentage of labeled cells among total or as the mean fluorescence intensity.
Immunofluorescence microscopy. B cells, pre-incubated or not for 15 min
at 37 °C with red Mitotracker (500 nM, Life Technologies) were loaded on poly-L-lysine-
coated slides, fixed in 3.7% paraformaldehyde, permeabilized with phosphate-buffered
saline (PBS)/0.1% Triton X-100 for 5 min at room temperature and incubated in 1 ×
PBS/5% bovine serum albumin (BSA) for 1 h at 37 °C in the presence of primary
antibodies. The latter were murine anti-pSTAT3Ser727 antibodies (BD Biosciences),
rabbit anti-pSTAT3Ser727 and anti-total STAT3 antibodies (Cell Signaling Technology,
Danvers, MA, USA), and antibodies directed to the Mt DNA-encoded complex I
(NADH-ubiquinone reductase) subunit (mtND1, gift of Dr. Lombes).16 Rabbit pSTAT3-
Ser727 antibodies were pre-mixed or not with the indicated pSTAT3-Ser727 peptide
(Santa Cruz) at a 1 : 1 concentration ratio. Then, FITC-conjugated anti rabbit
immunoglobulin G antibody (BD Biosciences) or PE-conjugated anti-murine
immunoglobulin G (Life Technologies) secondary antibodies were used for 1 h
incubation at room temperature. Slides were DAPI-stained and viewed using a Leica
confocal microscope (LEICA,Wetzlar, Germany), with a digital AxioCamERc camera
and analyzed with AxioVisio software (Carl Zeiss, Jena, Germany). At least 25 cells/
patient sample were observed at × 63 and × 100 magnifications. Co-localization
analyses used a cooled Coolsnap camera (Roper Scientific, Trenton, NJ, USA) with
optical z-sections collected at 0.63 μm steps. Image analyses were performed with the
software ImageJ associated with the JACoP plugin tool to integrate statistics to spatial
exploration of correlated pixel signals (expressed as Pearson’s correlation coefficient).
Coefficients 40.5 indicated significant colocalization.39
Transmission electron microscopy. B cells were fixed in 3% glutar-
aldehyde and postfixed in 1 × PBS/1% osmium tetroxide, dehydrated in ethanol
followed by propylene oxide (VWR, Radnor, PA, USA), embedded in Epon and
polymerized overnight at 60 °C. Ultrathin sections were cut with a LEICA/Reichert
Ultracut S ultramicrotome, stained with uranyl acetate and lead citrate.
Immunolabeling was performed on B cells fixed in 0.2% glutaraldehyde/4%
paraformaldehyde for 1 h at room temperature as described,40 using rabbit total
STAT3 or pSTAT3Ser727 antibodies (Cell Signaling Technology). Ultrathin (Peabody,
MA, USA) sections were examined with a JEOL1011 transmission electron
microscope. Digital images of ≥ 10 cells/sample were obtained using a GATAN-
CCD camera and Digital Micrograph software (Warrendale, MA, USA).
Preparation of mitochondria extracts. Mitochondria were isolated from
B cells using Mitochondria isolation kit (Miltenyi Biotec) following manufacturer’s
instructions with some modifications. Briefly, frozen B cells (2–10 × 107 cells) were
directly resuspended in pre-cooled phosphate-buffered saline (1 ml per 108 total
cells) supplemented with ethylenediamine tetraacetatic acid (EDTA; 2 mM), anti-
protease and –phosphatase inhibitors and benzonase (50 U), and incubated for
20 min at 4 °C. Cell homogenization was performed with a 26-G needle stepwise
using 5–10 stokes. Lysates were diluted to 1 × separation buffer (Miltenyi Biotec)
and proceeded to magnetic labeling by incubation with anti-Tom22 magnetic beads
for 1 h at 4 °C on a wheel. The labeled cell lysate was loaded on a MACS column
placed in a magnetic field and let run through. Lysates were re-loaded three times.
Column was then intensively washed out and the magnetically labeled mitochondria
were then flushed out. Pre- and post-mitochondria-purified fractions were separated
by SDS-PAGE and the presence of cytoplasmic β-actin protein, Mt hsp60 or
NDUFA9 proteins, and nuclear KDM1a were evaluated by western blot analysis
using monoclonal anti-β-actin (AC-15, Sigma-Aldrich), -hsp60 (Biosciences Inc.,
Allentown, PA, USA), -NDUFA9 (Abcam, Cambridge, UK) and KDM1a
(Cell Signaling Technology).
Immunoprecipitation. Total cell extracts from B cells (5 107) were obtained
by a 30-min incubation at 4 °C in lysis buffer (20 mM Tris, pH 8, 137 mM NaCl, 1%
NP40, 10% glycerol and 2 mM EDTA) supplemented with cocktails of proteinase
(Roche) and phosphatase inhibitors. Lysates were immunoprecipitated for 4 h at
4 °C with 4 μg of complex I immunocapture monoclonal antibody (MitoSciences,
Eurogen, OR, USA) or isotype-matched control (ctl). Immunoprecipitates were
separated by SDS-PAGE and immunoblotted with the indicated antibodies.
Oligo pull-down assays. Cytoplasmic and nuclear extracts were obtained
from B cells, as previously described.41 To confirm proper subcellular fractionation,
extracts were separated by SDS-PAGE and the presence of the nuclear lamin B and
A/C, or the cytoplasmic β-actin was assessed by western blot analysis using
monoclonal mouse anti-β-actin (Sigma-Aldrich), polyclonal rabbit anti-lamin B,
-lamin A/C (Cell Signaling Technology) antibodies. Nuclear extracts (2–5 × 107) were
incubated with 1 μg of the indicated biotin-labeled STAT3-DNA probe SIE367
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(5′-TTCCCGTAA-3′) or IRF1 (5′-GATCCATTTCCCCGAAATGA-3′) or control Oct-
DNA probe (5′-CGGGTATAATTTCTGC-3′) in binding buffer (10 mM HEPES,
100 μM EDTA, 50 mM NaCl, 50 mM KCl, 5 mM MgCl2, 4 mM spermidine, 2 mM
dithiothreitol, 0.1 mg of BSA/ml, 2.5% glycerol and 4% Ficoll) for 2 h at 4 °C, as
described.41 Streptavidin magnetic beads (Pierce, Thermo Fisher Scientific) were
added for 30 min at 4 °C, extensively washed, resuspended in SDS-PAGE loading
buffer and analyzed by SDS-PAGE and immunoblotting.
Statistics. Data were expressed as means or medians depending on the normality
of the distribution. Statistical significance was determined by Student’s t-test or Mann–
Whitney/Wilcoxon test. P-values≤ 0.05 were considered as significant (*) and P-values
≤ 0.01 as highly significant (**). Statistical analyses were performed with the Medcalc
(Ostende, Belgium) and GraphPad Prism softwares (San Diego, CA, USA).
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